The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277
RetractedRETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 131
RetractedAmar, F., Sherman, M. A., Rush, T., Larson, M., Boyle, G., Chang, L., Götz, J., Buisson, A., & Lesné, S. E. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 112
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 6×
“dence that AD is a transmissible prion-like disease [5], experimental data support the idea that A Os may spread from cell-to-cell and brain region-toregion in a prion-like manner.”
BackgroundInfluentialAmyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Items 701–800 of 867
Yang, Y., & Kwak, Y. T. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261441816 · Cited by 1
Flores-Melivilu, D., Carrazana, E., García, N., Alarcón, S., Caru-Ruiz, M., Chacón-Fuentes, M., Santos, N., Ahumada, M., Nova, E., Díaz‐Espinoza, R., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05855-3 · Cited by 1
Garcia, S. G., Almardini, A. A., Pereira, A. J., Xing, H., Knox, L. J., Jimenez, J. V., Webster-Ford, J. C., Moyá, D. A., Payne, J. C., Dawes, C. K., et al. (2026) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6c00503 · Cited by 1
An islet amyloid polypeptide oligomer model inhibits fibril formation
Pfitzer, A., Schulz, C. M., Backer, R., Hasecke, F., Gremer, L., & Hoyer, W. (2026) · Biophysical Chemistry · doi:10.1016/j.bpc.2026.107642 · Cited by 1
Stepanchuk, A. A., Joseph, J. T., Lashley, T., & Stys, P. K. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.04.009 · Cited by 1
The mitochondria-synapse axis in Alzheimer’s disease: Lost coordination in early stages
Sharma, P., Kaur, N., Vasal, N., Solanki, K., & Sunkaria, A. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103168 · Cited by 2
Bian, X., (163589), J. Z., Liu, Z., Zhang, W.-P., Liu, X., Cao, Y., Liu, J.-G., Zhao, D., Zhang, H., Chen, H., et al. (2026) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2026.140322 · Cited by 1
Martins, G. F., Rocha, C., & Galamba, N. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00242 · Cited by 1
Arriagada, J., Ardiles, Á. O., Mery, E., Garay, C., Conejera, F., Herrera, E. A., Paula-Lima, A. C., & Muñoz, P. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111116 · Cited by 1
Bioinformatics-Based Analysis of Circadian Rhythm Regulation Mechanisms in Alzheimer’s Disease
Zhang, J., Gao, S., & Liu, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230177 · Cited by 1
Taniwa, K., Murakami, K., Sakaguchi, Y., Izuo, N., Hanaki, M., Sampa, N., Kume, T., Shimizu, T., & Irie, K. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c02598 · Cited by 1
A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs
Smeralda, W., Since, M., Corvaisier, S., Fayolle, D., Cardin, J., Duprey, S., Jourdan, J., Cullin, C., & Malzert‐Fréon, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316982 · Cited by 1
Ichimata, S., Hata, Y., Yoshida, K., & Nishida, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147581 · Cited by 1
Iida-Adachi, A., & Nabika, H. (2025) · Langmuir · doi:10.1021/acs.langmuir.4c03663 · Cited by 2
Targeting amyloidogenic proteins through cyclic peptides – A medicinal chemistry perspective
Zargaham, M. K., Ibrahim, A., Ahmed, M., Babar, M. M., & Rajadas, J. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118165 · Cited by 1
The Importance of Vaccines in Preventing Impending Alzheimer’s Epidemic
Tripathi, S., Sharma, Y., & Kumar, D. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871357356250325071712 · Cited by 1
Fukase, K., Iida-Adachi, A., & Nabika, H. (2025) · ACS Omega · doi:10.1021/acsomega.5c02756 · Cited by 1
Akasaka, T., Watanabe, H., & Ono, M. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00525 · Cited by 2
Advances in Probing Amyloid Heterogeneity Using Vibrational Spectroscopy and Imaging
Rohler, C. K., Hess, K. A., & Buchanan, L. E. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c06431 · Cited by 2
Kabbani, M. A. A., Köhler, L., Wied, T., Adam, D., Klimek, J., & Zempel, H. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18081038 · Cited by 2
Molecular mechanisms of amyloid aggregation in human proteinopathies
Morel, B., & Conejero‐Lara, F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819132-3.00008-7 · Cited by 2
Neurodegenerative damage reduces firing coherence in a continuous attractor model of grid cells
Zhi, Y., & Cox, D. L. (2021) · Physical review. E · doi:10.1103/physreve.104.044414 · Cited by 1
Supramolecular Bait to Trigger Non‐Equilibrium Co‐Assembly and Clearance of Aβ42
Wu, T., Lai, R., Yao, C., Juang, J., & Lin, S. (2020) · Angewandte Chemie · doi:10.1002/ange.202013754 · Cited by 1
Amyloid-β in Brain Aging and Alzheimer’s Disease
Sasaguri, H., & Saido, T. C. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_21 · Cited by 3
Preparation and Investigation of Crucial Oligomers in the Early Stages of Aβ40 and Aβ42 Aggregation
Morel, B., & Conejero‐Lara, F. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2597-2_2 · Cited by 1
Mai, T. L., Nguyen, H. T., Derreumaux, P., & Nguyen, P. H. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26508 · Cited by 4
Soluble Aβ Oligomers Formed Channels Leading to Calcium Dysregulation
Li, S. (2023) · Function · doi:10.1093/function/zqad037 · Cited by 1
Serotonin receptors - a potential target for the treatment of Alzheimer’s disease
Eremin, D. V., Kondaurova, E. M., Rodnyy, A. Y., Molobekova, K. A., Kudlay, D. A., & Naumenko, V. S. (2023) · Biochemistry (Moscow) · doi:10.31857/s0320972523120059 · Cited by 1
Vosough, F., Carstensen, S. M., Baronio, C. M., & Barth, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.31.646305 · Cited by 1
Azouz, M. (2019) · theses.fr (ABES) · doi:10.70675/4c3b6c12z1da5z497cz9e34zea6e6bf189d9 · Cited by 2
APP-CTFβ/C99 Oligomers Drive Synaptic Vesicle Tethering through C-Terminal InteractionsPreprint
Kapadia, A., Cijffers, E., Van, S., & Hafner, A. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7162192 · Cited by 1
Nutrition, Inflammation, and Infection in the Genomics of Lifespan
Finch, C. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11297-8
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6 · Cited by 1
Diagnosi clinicolaboratoristica della malattia di Alzheimer
Lagarde, J., Olivieri, P., Bottlaender, M., & Sarazin, M. (2021) · EMC - Neurologia · doi:10.1016/s1634-7072(21)45320-1 · Cited by 1
Ramírez‐Toraño, F. (2021) · UPM Digital Archive (Technical University of Madrid) · doi:10.20868/upm.thesis.66243
Research and Development of Vaccines for Alzheimer's Disease
Kaminaka, K., & Nozaki, C. (2019) · International Journal of Recent Innovations in Academic Research
Shea, Y. F., & DeKosky, S. T. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_665
Alzheimer’s disease as a syndrome of overloaded amyloidic synaptic tagging in memory networksPreprint
Murphy, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7gsaz
A Meta-Analysis Study on Alzheimer’s Disease
(2021) · Journal of Bioscience & Biomedical Engineering · doi:10.47485/2693-2504.1050
Duffin, J. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736901473.793567387
Cannabidiol-Mediated Sequestration of Alzheimer’s Amyloid-β Peptides in ADDL Oligomers
Li, Y., Zhang, F., Herron, C. E., Rosales, I., Heredia, A., Buchete, N., & Rodriguez, B. J. (2023) · American Journal of Molecular Biology · doi:10.4236/ajmb.2023.132008
Real‐Time Observation for Dynamic Oscillation during Self‐Assembly and Clearance of Aβ42
Yao, C., Wu, T., Cheng, P., Tsao, Y., Lu, Y., Chu, L., Chiu, C., & Lin, S. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202300142
Ganguly, A. K., Ramaswamy, L., Watanabe, S., Ide, N., Kinjo, M., & Harada, A. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04706
Magnesium and Alzheimer's disease
Toffa, D. H., & Li, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89835-5.00032-6 · Cited by 1
High-Throughput Searches for Natural Products as Aggregation Modulators of Amyloidogenic Proteins
Murakami, K. (2023) · Springer eBooks · doi:10.1007/978-981-99-1714-3_15
Alzheimer’s Research Gains Momentum and Spreads Out
Behl, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31570-1_14
Hemodiyaliz Hastalarında Kateter İlişkili Enfeksiyon Etkenleri
Kaya, H. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1668
Menstrüel Siklusun Evrelerinin Uyku, İştah ve Vücut Ağırlığı Üzerine Etkileri
Özüpek, G., & Altay, S. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1671
Metabolik Hastalıklarda Asprosinin Rolü
Akçılar, R. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1669
Metisilin Dirençli Staphylococcus aureus (MRSA)
Sağlam, M., Kılıç, İ. H., & Zer, Y. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1677
Fahrioğlu, S. L., Yılmaz, İ., & İlgi, S. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1675
İyonlaştırıcı Olmayan Radyasyonun Yaşamımızdaki Yeri
Yavaş, M. C. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1673
Amiloid Beta Peptidler: in-vitro Alzheimer Hastalığı Toksisite Modellerinde Kullanımları
Kurt, S., & Çam, F. S. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1678
Dalak Anatomisi ve Klinik Önemi
Erbek, E., & BOLATLI, G. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1674
Gebelikte Parasetamol (Asetaminofen) Kullanımı Güvenli mi?
Şen, F. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1676
Köse, H. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1670
Coşar, A. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1672 · Cited by 1
Sağlık Bilimleri Araştırmaları: Temel Tıp- IV
Kaya, H., Ibrahim Halil GAZIANTEP UNIVERSITY KILIC, Akçılar, R., Köse, H., Özüpek, G., Altay, İ. S., Coşar, A., Yavaş, M. C., Erbek, E., BOLATLI, G., et al. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384
Yerel bir virüsten Yeni Bir Epidemiye mi? Maymun Çiçeği Virüsü (Monkeypox) Virüsü Yapısı
Bozlak, Ç. E. B. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1681
Salmonella spp. Enfeksiyonları
Gümüşburun, S. A., Demirdöğen, Y., Vural, U., Boyraz, E. F., & Eslami, M. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1679
Effects of Radiofrequency Radiations on the Male Reproductive System
Yavaş, M. C. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub384.c1680
The nature of tyrosine-aminated amyloid-βPreprint
Gao, Z., Hu, T., Wu, J., Fu, S., & Li, H. (2024) · Research Square · doi:10.21203/rs.3.rs-3752850/v1
Molecular mechanism of Alzheimer’s β-amyloid peptide aggregation
Li, Y., Mao, X., Liu, K., & Niu, Z. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1167
Each big journey starts with a first step: Importance of oligomerization
Agha, M. M., Aziziyan, F., & Uversky, V. N. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.011
Bai, B., Vanderwall, D., Li, Y., Wang, X., Poudel, S., Wang, H., Dey, K. K., Chen, P., Yang, K., & Peng, J. (2021) · Figshare · doi:10.6084/m9.figshare.15162179
Mee-inta, O., Chiang, Y.-Y., Zhao, Z., Wang, T.-F., Lee, H., Huang, C., Wu, P., & Kuo, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4234881/v1
The Genetics of Alzheimer’s Disease and the role of non-long coding RNAs in disease pathogenesis
Roy, S., Biswas, S., Guha, D., Dasgupta, R., & Bagchi, A. (2024) · doi:10.52756/bhstiid.2024.e01.001
hWJ-MSC Reduces IL-1β Gene Expression in Alzheimer's Rat Models
Afriani, N., Darwin, E., & Ali, H. (2024) · International Journal of Research and Review · doi:10.52403/ijrr.20240702
Yang, Y., Huh, K., & Kwak, Y. T. (2024) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14958
Lloyd, C., Freskgård, P., Newton, P., Lowne, D., Nickson, A. A., Bogstedt, A., Eketjäll, S., Höglund, K., Gustavsson, S., Welsh, F., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14238 · Cited by 1
Kang, W., Lü, Y., Etaka, J. C. E., Salsbury, F. R., & Derreumaux, P. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c03308
Farnum, Z., Mani, R., Bindoff, A. D., Wilson, R., Fiotakis, A., Stephens, J., Cho, H., Mackay‐Sim, A., & Sinclair, D. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16263
Luo, S., Xu, X., Liu, J., Tang, B., Zhang, J. Z. H., & Duan, L. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.126562
Матухно, А. Е., Tkacheva, P. V., Voinov, V. B., Lysenko, L. V., Evsyukova, E. V., Taisaeva, A. O., & Борисович, Б. И. (2024) · Журнал высшей нервной деятельности им И П Павлова · doi:10.31857/s0044467724060084
Wan, Z., Ren, Q., Li, Q., Liu, Z., Wang, S., & Shi, X. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149389
Therapeutic Role of Scutellarein in Neurological Disorders
Kumar, R., Bai, S., Shukla, R., & Naqvi, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128336901241125092132
Hervé, V., Bonenfant, L., Amyot, M., Balafrej, R., Ali, O. B. K., Benali, H., & Brouillette, J. (2025) · STAR Protocols · doi:10.1016/j.xpro.2025.103712
Lapcinski, I. P., Petersen, A. J., Ashe, K. H., & Liu, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.11.648457
Ayon, N. J. (2025) · Preprints.org · doi:10.20944/preprints202507.0464.v1
Ayon, N. J. (2025) · Preprints.org · doi:10.20944/preprints202507.0464.v2
Ruttenberg, S. M., Dhaoui, R., Kreutzer, A. G., & Nowick, J. S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331024 · Cited by 1
Infusion of blood from young and old mice modulates amyloid pathology
Pizarro, M., Gomez‐Gutierrez, R., Caviedes, A., Valdes, C., Woehlbier, U., Vargas, C., Hernández, M., Duran-Aniotz, C. A., & Morales, R. (2025) · Aging · doi:10.18632/aging.206319 · Cited by 1
Bigi, A., Napolitano, L., Vadukul, D. M., Chiti, F., Cecchi, C., Aprile, F. A., & Cascella, R. (2024) · Figshare · doi:10.6084/m9.figshare.25025878
Chen, S., Guo, D., Zhu, Y., Xiao, S., Xie, J., Zhang, Z., Hu, Y., Huang, J., Ma, X., Ning, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25397542
Chen, S., Guo, D., Zhu, Y., Xiao, S., Xie, J., Zhang, Z., Hu, Y., Huang, J., Ma, X., Ning, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25397692
Laversenne, V., Nazeeruddin, S., Källstig, E., Colin, P., Voize, C., & Schneider, B. L. (2020) · Figshare · doi:10.6084/m9.figshare.13278564
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24844648
Laversenne, V., Nazeeruddin, S., Källstig, E., Colin, P., Voize, C., & Schneider, B. L. (2020) · Figshare · doi:10.6084/m9.figshare.13278558
Chen, S., Guo, D., Zhu, Y., Xiao, S., Xie, J., Zhang, Z., Hu, Y., Huang, J., Ma, X., Ning, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26692306
Laversenne, V., Nazeeruddin, S., Källstig, E., Colin, P., Voize, C., & Schneider, B. L. (2020) · Figshare · doi:10.6084/m9.figshare.13278567
Laversenne, V., Nazeeruddin, S., Källstig, E., Colin, P., Voize, C., & Schneider, B. L. (2020) · Figshare · doi:10.6084/m9.figshare.13278561
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24844709
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26654539
Vandenabeele, M., Veys, L., Lemmens, S., Hadoux, X., Gelders, G., Masin, L., Serneels, L., Theunis, J., Saito, T., Saido, T. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13531796
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26654542
Vandendriessche, C., Balusu, S., Cauwenberghe, C. V., Brkic, M., Pauwels, M. J., Plehiers, N., Bruggeman, A., Dujardin, P., Imschoot, G. V., Wonterghem, E. V., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16417667
Laversenne, V., Nazeeruddin, S., Källstig, E., Colin, P., Voize, C., & Schneider, B. L. (2020) · Figshare · doi:10.6084/m9.figshare.13278573
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26654536
Laversenne, V., Nazeeruddin, S., Källstig, E., Colin, P., Voize, C., & Schneider, B. L. (2020) · Figshare · doi:10.6084/m9.figshare.13278555
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.